|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,290,000 |
Market
Cap: |
266.54(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.55 - $11.69 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sera Prognostics is a women's health company. Co.'s primary commercial product, the PreTRM test, is a commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during week 19 or 20 of gestation that provides a prediction of the expectant mother's risk of delivering spontaneously before 37 weeks' gestation. Co. is discovering and developing several additional biomarker tests to predict other conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
8,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$9,600 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
212,353 |
287,115 |
292,115 |
325,090 |
Total Sell Value |
$1,998,464 |
$2,554,554 |
$2,570,704 |
$2,624,320 |
Total People Sold |
6 |
6 |
6 |
6 |
Total Sell Transactions |
17 |
25 |
26 |
40 |
End Date |
2024-02-13 |
2023-11-12 |
2023-05-14 |
2022-05-14 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Boniface John J. |
Chief Scientific Officer |
|
2022-03-22 |
4 |
AS |
$3.68 |
$10,028 |
D/D |
(2,725) |
95,560 |
|
-39% |
|
Boniface John J. |
Chief Scientific Officer |
|
2022-03-14 |
4 |
AS |
$3.94 |
$10,737 |
D/D |
(2,725) |
98,285 |
|
-52% |
|
Boniface John J. |
Chief Scientific Officer |
|
2022-03-11 |
4 |
OE |
$0.73 |
$55,479 |
D/D |
75,998 |
101,010 |
|
- |
|
Boniface John J. |
Chief Scientific Officer |
|
2021-12-06 |
4 |
OE |
$0.73 |
$18,259 |
D/D |
25,012 |
25,012 |
|
- |
|
Critchfield Gregory C |
Chief Executive Officer |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
84,973 |
794,945 |
|
- |
|
Trimble Ryan |
Director |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
I/I |
63,005 |
100,554 |
|
- |
|
Moyes Jay M |
Chief Financial Officer |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,830 |
2,830 |
|
- |
|
Bxhcp Sp Iii, Llc |
10% Owner |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
I/I |
3,795,150 |
1,204,508 |
|
- |
|
Phillips Joshua |
Director |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
I/I |
927,562 |
965,111 |
|
- |
|
84 Records found
|
|
Page 4 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|